Literature DB >> 20844851

[Oncological pelvic surgery under urological aspects: bladder carcinoma].

H Kübler1, J E Gschwend.   

Abstract

The aim of the treatment of invasive bladder cancer with radical cystectomy and subsequent urinary diversion is to combine a safe oncological procedure with a satisfactory quality of life. Radical cystectomy is the treatment of choice for all patients with recurrent or multifocal high grade T1 bladder cancer, T1 tumors with high risk of progression, failure of Bacillus Calmette-Guérin treatment and muscle-invasive bladder cancer. Radical cystectomy offers excellent recurrence-free and cancer-specific survival rates as well as local tumor control in patients with organ-confined and node-negative diseases. Tumor control in non-organ-confined tumors is still satisfactory with long term recurrence-free survival (RFS) rates of about 50%. Nerve-sparing cystectomy is of importance for lower urinary tract function, including continence rates after orthotopic urinary diversion and for sexual function in males and females. Orthotopic urinary reconstruction using a neobladder achieves good continence rates. Overall quality of life after radical cystectomy remains good in most patients irrespective of the type of urinary diversion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844851     DOI: 10.1007/s00104-010-1943-1

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  17 in total

1.  The value of a second transurethral resection for T1 bladder cancer.

Authors:  Hartwig E Schwaibold; Sivaprakasam Sivalingam; Florian May; Rudolf Hartung
Journal:  BJU Int       Date:  2006-03-23       Impact factor: 5.588

2.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

3.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

Authors:  Stephan Madersbacher; Werner Hochreiter; Fiona Burkhard; George N Thalmann; Hansjörg Danuser; Regula Markwalder; Urs E Studer
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

4.  The value of a second transurethral resection in evaluating patients with bladder tumors.

Authors:  H W Herr
Journal:  J Urol       Date:  1999-07       Impact factor: 7.450

5.  Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?

Authors:  Harry W Herr; S Machele Donat; Guido Dalbagni
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

Review 6.  The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.

Authors:  J Alfred Witjes; Jude Douglass
Journal:  Nat Clin Pract Urol       Date:  2007-10

7.  Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup.

Authors:  M P Schoenberg; P C Walsh; D R Breazeale; F F Marshall; J L Mostwin; C B Brendler
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

8.  Outcome and quality of life in patients operated on with radical cystectomy and three different urinary diversion techniques.

Authors:  Pål Stefan Frich; Camilla Angelsen Kvestad; Anders Angelsen
Journal:  Scand J Urol Nephrol       Date:  2009

9.  Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment.

Authors:  U E Studer; H Danuser; V W Merz; J P Springer; E J Zingg
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

10.  The ileal neobladder: complications and functional results in 363 patients after 11 years of followup.

Authors:  R E Hautmann; R de Petriconi; H W Gottfried; K Kleinschmidt; R Mattes; T Paiss
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.